Flash CGM Is Associated With Reduced Diabetes Events and Hospitalizations in Insulin-Treated Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Purpose: Suboptimal glycemic control among individuals with diabetes is a leading cause of hospitalizations and emergency department utilization. Use of flash continuous glucose monitoring (flash CGM) improves glycemic control in type 1 and type 2 diabetes, which may result in lower risk for acute and chronic complications that require emergency services and/or hospitalizations. Methods: In this retrospective, real-world study, we analyzed IBM MarketScan Commercial Claims and Medicare Supplemental databases to assess the impact of flash CGM on diabetes-related events and hospitalizations in a cohort of 2463 individuals with type 2 diabetes who were on short- or rapid-acting insulin therapy. Outcomes were changes in acute diabetes-related events (ADE) and all-cause inpatient hospitalizations (ACH), occurring during the first 6 months after acquiring the flash CGM system compared with event rates during the 6 months prior to system acquisition. ICD-10 codes were used to identify ADE for hypoglycemia, hypoglycemic coma, hyperglycemia, diabetic ketoacidosis, and hyperosmolarity. Results: ADE rates decreased from 0.180 to 0.072 events/patient-year (hazard ratio [HR]: 0.39 [0.30, 0.51]; P < 0.001) and ACH rates decreased from 0.420 to 0.283 events/patient-year (HR: 0.68 [0.59 0.78]; P < 0.001). ADE reduction occurred regardless of age or gender. Conclusions: Acquisition of the flash CGM system was associated with reductions in ADE and ACH. These findings provide support for the use of flash CGM in type 2 diabetes patients treated with short- or rapid-acting insulin therapy to improve clinical outcomes and potentially reduce costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Personalized nutrition by prediction of glycemic responses
Zeevi, D., Korem, T., Zmora, N., Israeli, D., Rothschild, D., Weinberger, A., Ben-Yacov, O., Lador, D., Avnit-Sagi, T., Lotan-Pompan, M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.001 · Cited by 2,929
Economic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 2×
“However, randomized controlled trials have demonstrated that use of continuous glucose monitoring (CGM) significantly lowers HbA1c [13], with reductions in hypoglycemia [14, 15] and improved treatment satisfaction [13, 14] in various type 2 diabetes populations.”
BackgroundMethodGregg, E. W., Cheng, Y. J., Srinivasan, M., Lin, J., Geiss, L. S., Albright, A. L., & Imperatore, G. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30314-3 · Cited by 480 · cited 1×
“Additionally, although cardiovascular disease remains the leading cause of mortality in both type 1 and type 2 diabetes, we are seeing an emergence in infectious, respiratory, renal, and liver diseases, which are likely attributable to persistent hyperglycemia [31].”
BackgroundPoor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes
Punthakee, Z., Miller, M. E., Launer, L. J., Williamson, J. D., Lazar, R. M., Cukierman-Yaffee, T., Seaquist, E. R., Ismail-Beigi, F., Sullivan, M. D., Lovato, L. C., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1855 · Cited by 337
Self-citationHypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes
Bremer, J. P., Jauch-Chara, K., Hallschmid, M., Schmid, S., & Schultes, B. (2009) · Diabetes Care · doi:10.2337/dc09-0114 · Cited by 298
Charleer, S., De Block, C., Van Huffel, L., Broos, B., Fieuws, S., Nobels, F., Mathieu, C., & Gillard, P. (2020) · Diabetes Care · doi:10.2337/dc19-1610 · Cited by 261
Multiple hospitalizations for patients with diabetes
Jiang, H. J., Stryer, D., Friedman, B., & Andrews, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1421 · Cited by 261
Fear of hypoglycaemia in parents of young children with type 1 diabetes: A systematic review
Barnard, K., Thomas, S., Royle, P., Noyes, K., & Waugh, N. (2010) · BMC Pediatrics · doi:10.1186/1471-2431-10-50 · Cited by 239 · cited 1×
“Apart from its acute clinical outcomes, episodes of severe hypoglycemia can impact patient adherence to therapy, which can lead to poor glycemic control and increased risk of long-term complications [24, 25].”
Background
Cited by
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus
Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00973-1 · Cited by 117
Riveline, J.-P., Roussel, R., Vicaut, E., de Pouvourville, G., Detournay, B., Emery, C., Levrat-Guillen, F., & Guerci, B. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0085 · Cited by 64
Harris, S., Cimino, S., Nguyen, Y., Szafranski, K., & Poon, Y. (2025) · Diabetes Therapy · doi:10.1007/s13300-024-01677-5 · Cited by 12
“The rate of NSHE was based on published studies [14, 31, 35] and was conservatively assumed not to be reduced with FreeStyle Libre among persons living with T2DM who were not using insulin.”
Continuous Glucose Monitoring for Type 2 Diabetes: How Does It Compare with Type 1 Diabetes?
Beck, R. W., & Bergenstal, R. M. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0374 · Cited by 12
“…fewer hospitalizations for individuals with T2D in the 6 months after starting CGM compared with the claims data for 6 months before starting CGM. 20 There remains a need to conduct cost-effectiveness studies for CGM in T2D, since the cost-benefit of CGM in T2D may not be the same as it is in T1D.”
InfluentialSelf-citationRatzki-Leewing, A., Harris, S. B., Rabasa-Lhoret, R., & Poon, Y. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0609 · Cited by 3
“7,16,17 However, there is a lack of population-based data on the effectiveness of FSL in Canada.”
Metadata
- Authors
- Bergenstal, R. M., Kerr, M. S. D., Roberts, G. J., Souto, D., Nabutovsky, Y., & Hirsch, I. B.
- Venue
- Journal of the Endocrine Society
- Publisher
- The Endocrine Society
- Published
- 2021-02-02
- Volume
- 5
- Issue
- 4
- Pages
- bvab013-bvab013
- ISSN
- 2472-1972 (ISSN-L)
- OpenAlex
- W3126724397
- Cited by
- 89
- References
- 18
- FWCI
- 8.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.